Newsroom | 12471 results

LITTLETON, Mass.--(BUSINESS WIRE)--Mevion Medical Systems, the global leader in compact proton therapy, today announced that it has been selected to deliver the MEVION S250-FIT Proton Therapy System™ to Istituto Nazionale Tumori IRCCS Fondazione G. Pascale in Naples. The award, made following a competitive European tender, will establish the first proton therapy center in Southern Italy, significantly expanding access to advanced radiation therapy for patients across the region and reducing the...

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) has been approved by the US Food and Drug Administration (FDA) for both the neoadjuvant and adjuvant treatment of patients with HER2-positive early breast cancer based on results from the DESTINY-Breast11 and DESTINY-Breast05 Phase III trials, respectively. In the neoadjuvant setting, ENHERTU followed by a taxane, trastuzumab, and pertuzumab (THP) has been approved for the treatment of...

TOKYO--(BUSINESS WIRE)--Enhertu Approved in the U.S. for Two New Indications for Patients with HER2 Positive Early Breast Cancer...

WAYNE, Pa.--(BUSINESS WIRE)--Teleflex Incorporated (NYSE: TFX) announced today that its Board of Directors declared a quarterly cash dividend of thirty-four cents ($0.34) per share of common stock. The dividend is payable June 30, 2026, to shareholders of record at the close of business on May 25, 2026. About Teleflex Incorporated As a global provider of medical technologies, Teleflex is driven by our purpose to improve the health and quality of people’s lives. Through our vision to become the...

BOSTON--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, is scheduled to present at Jefferies Global Healthcare Conference on Thursday, June 4, 2026, in New York, NY. About Novanta Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original equipment manufacturers a competitive...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROP; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Tecentriq® (atezolizumab) and Tecentriq Hybreza® (atezolizumab and hyaluronidase-tqjs) as an adjuvant treatment for adult patients with muscle-invasive bladder cancer (MIBC) who have circulating tumor DNA molecular residual disease (ctDNA MRD) after cystectomy, as identified by Natera’s Signatera™ CDx per...

MISSISSAUGA, Ontario--(BUSINESS WIRE)--Covalon Technologies Ltd. (the "Company" or "Covalon") (TSXV: COV; OTCQX: CVALF), an advanced medical technologies company, will release its Q2 Fiscal 2026 results on Thursday, May 21, 2026, before markets open. A conference call and webcast to discuss the results will be held on Thursday, May 21, 2026, at 8:30am ET. To view, listen to, and participate in the live webcast, please follow the link below: https://events.q4inc.com/attendee/485973962 To listen...

MANHASSET, N.Y.--(BUSINESS WIRE)--The American Association of Neurological Surgeons (AANS) has named Kevin J. Tracey, MD, president and CEO of Northwell Health’s Feinstein Institutes for Medical Research, as the 2026 recipient of its esteemed Cushing Award for Technical Excellence and Innovation in Neurosurgery. This top honor recognizes Dr. Tracey’s unparalleled contributions, including 120 U.S. patents and 400 scientific publications, which reshaped the understanding of neuro-immune communica...

LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the first quarter ended April 3, 2026. First Quarter 2026 Financial Overview Net sales of $93.5 million, up 119.6% Y/Y Net sales excluding China of $46.1 million, up 6.0% Y/Y Gross margin at 73.6% vs. 65.8% a year ago Net income of $5.2 million or $0.10 per diluted share, com...

MENLO PARK, Calif.--(BUSINESS WIRE)--Tutor Perini Corporation (NYSE: TPC) (the “Company”), a leading civil, building and specialty construction company, announced today that its subsidiary, Rudolph and Sletten, has been awarded a contract by Sutter Health for its future Advanced Orthopedics & Sports Medicine Care Complex in Sacramento, California. The project scope of work includes the conversion of the existing 660 J Street office building into a new approximately 120,000 square-foot ambul...